Skip to main content
Fig. 1 | Journal of Medical Case Reports

Fig. 1

From: Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report

Fig. 1

Clinical course: blood laboratory values from initial baseline assessment through 30 days post CAR T cell administration. LDC was administered on days -47 and days -5 through -3; positive COVID-19 test by PCR day -46, negative COVID-19 test by PCR day -7; CAR T cell administration day 1, anti-viral antibody titer day -7. Repeat anti-viral antibody titers were conducted day 43 and day 73 (not shown)

Back to article page

Journal of Medical Case Reports

ISSN: 1752-1947